CREBBP


Also found in: Dictionary, Medical, Financial, Encyclopedia.
Related to CREBBP: EP300
AcronymDefinition
CREBBPCREB-Binding Protein
References in periodicals archive ?
The results showed that the expression of acetyltransferase CREBBP in LADA patients was downregulated and the expression of histone deacetylase HDAC1 and HDAC7 was upregulated.
The product is a potent spectrum selective inhibitor of HDAC 1, 2, 3 and 11, and is being developed as a single agent treatment targeting mutations and deletions of the histone acetyltransferase genes CREBBP and EP300.The company stated that these genetic alterations are implicated in the pathogenesis and progression of bladder cancer and other solid tumour types and diffuse large B-cell lymphoma and follicular lymphoma.
More importantly, this euchromatin state is maintained through the expression of CDX2 and CREBBP. Although the involvement of OCT4 in the regulation of bovine IFNT gene transcription has been demonstrated (Ezashi et al., 2001), the relationship between CDX2, CREBBP, OCT4, and other transcription factors in IFNT gene transcription has not been carefully studied.
[5] Human genes: CBFB, core-binding factor, beta subunit; RUNX1, runt-related transcription factor 1; MAGI3, membrane associated guanylate kinase, WW and PDZ domain containing 3; AKT3, v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); MAGI3-AKT3, fusion of genes MAGI3 and AKT3; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; CT-NNB1, catenin (cadherin-associated protein), beta 1, 88kDa; SMARCA4, SWI/ SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; CREBBP, CREB-binding protein; WNT, wingless-type MMTV integration site family; BRAF, v-raf murine sarcoma viral oncogene homolog B1.
CREBBP, a gene involved in the Sri-lad pathway, was significantly up-regulated by NF3, which has been demonstrated to be a necessary co-activator for the Smad-dependent TGF-[beta] transcriptional response (Topper et al.
DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.